Improving guideline-concordant biomarker testing through implementation of a precision cancer medicine steward.

person Rifeta Kajdic Hodzic Association of Community Cancer Centers, Rockville, MD info_outline Rifeta Kajdic Hodzic, Elana Plotkin, Leigh Boehmer, Joseph Kim, Luis E. Raez, Crystal Enstad, Courtney Rice, Frank dela Rama

Authors person Rifeta Kajdic Hodzic Association of Community Cancer Centers, Rockville, MD info_outline Rifeta Kajdic Hodzic, Elana Plotkin, Leigh Boehmer, Joseph Kim, Luis E. Raez, Crystal Enstad, Courtney Rice, Frank dela Rama Organizations Association of Community Cancer Centers, Rockville, MD, Xaf Solutions, Newtown, PA, Memorial Cancer Institute, Pembroke Pines, FL, Sanford USD Medical Center, Sioux Falls, SD, Trihealth Cancer Institute, South Lebanon, OH, Palo Alto Medical Foundation, Palo Alto, CA Abstract Disclosures Research Funding Pharmaceutical/Biotech Company AstraZeneca and Blueprint Medicines Background: Gaps in guideline-concordant cancer biomarker testing exist in real-world clinical practice. Medically underserved populations, in particular, face significant challenges to accessing the latest advances in cancer diagnostics. As community cancer programs work to expand their approach to precision medicine, some have created a precision medicine “steward” who acts as a point person for removing barriers to biomarker testing. The Association of Community Cancer Centers (ACCC) explored the clinical utility, impact, and feasibility of having a precision medicine steward on the multidisciplinary cancer care team. Methods: ACCC held a series of focus groups and interviews with a diverse group of stakeholders to explore how cancer programs had justified, hired, trained, and utilized precision medicine stewards to improve guideline-concordant biomarker testing rates. ACCC examined select job descriptions, learned how stewards helped improve biomarker testing processes, and developed a framework for how a steward can fit into cancer care teams’ clinical and operational workflows. Results: Precision cancer medicine stewards can help improve biomarker test ordering processes. In one member program, turnaround time from test ordering to receipt of results decreased from an average of 24 days to 12 days and the quantity non-sufficient rate of testing decreased by five percent. Stewards also helped to improve the digitization of test orders, streamline prior authorizations, track tissue specimens, and notify oncologists when quantity of tissue was not adequate for testing. Stewards contributed to precision medicine workgroups that vetted reference laboratories, tracked key performance indicators around biomarker testing, and prioritized opportunities to reduce testing disparities. ACCC also collated examples of job titles, job descriptions, and role responsibilities of precision medicine stewards to share across member programs and practices. Conclusions: Guideline-concordant biomarker testing requires multiple complex steps and careful care coordination. Precision cancer medicine stewards have been shown to improve testing-related processes, decrease the time from ordering to receipt of results, and assist with prior authorizations. ACCC will work to further highlight their contributions on the multidisciplinary cancer care team and document more evidence of their return on investment for cancer programs and practices.